Scopus BioPharma (SCPS) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 08, 2023
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Entity File Number	001-39788
Entity Registrant Name	Scopus BioPharma Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-1248020
Entity Address, Address Line One	420 Lexington Avenue, Suite 300
Entity Address, City or Town	New York
Entity Address State Or Province	NY
Entity Address, Postal Zip Code	10170
City Area Code	212
Local Phone Number	479-2513
Title of 12(g) Security	Common Stock, par value $0.001 per share
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,784,264
Entity Central Index Key	0001772028
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 1,401,475	$ 124,575
Prepaid expenses and other current assets	199,818	265,425
Total current assets	1,601,293	390,000
Property and equipment, net	2,034	2,265
Total assets	1,603,327	392,265
Current liabilities:
Accounts payable and accrued expenses	9,151,750	7,201,926
Other current liabilities	161,462	252,508
Total current liabilities	9,313,212	7,454,434
COMMITMENTS AND CONTINGENCIES
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 20,000,000 shares authorized; zero shares issued and outstanding
Common stock, $0.001 par value; 50,000,000 shares authorized; 39,584,264 and 21,094,264 issued and outstanding at March 31, 2023 and December 31, 2022, respectively	39,584	21,094
Additional paid-in capital	48,543,332	46,518,455
Stock subscriptions receivable	(28,578)	(33,950)
Accumulated deficit	(55,514,797)	(53,064,975)
Accumulated other comprehensive income (loss)	13,475	(4,954)
Total Scopus BioPharma Inc. stockholders' equity (deficit)	(6,946,984)	(6,564,330)
Noncontrolling interest (deficit)	(762,901)	(497,839)
Total stockholders' equity (deficit)	(7,709,885)	(7,062,169)
Total liabilities and stockholders' equity (deficit)	$ 1,603,327	$ 392,265

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	39,584,264	21,094,264
Common stock, shares outstanding	39,584,264	21,094,264

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Revenues	$ 0	$ 0
Operating expenses:
General and administrative	1,070,734	4,291,666
Research and development	1,608,922	369,108
Total operating expenses	2,679,656	4,660,774
Net loss	(2,679,656)	(4,660,774)
Net loss attributable to noncontrolling interest (deficit)	(229,834)
Net loss attributable to Scopus BioPharma Inc.	(2,449,822)	(4,660,774)
Comprehensive income:
Foreign currency translation adjustment	18,429	17,866
Total comprehensive loss attributable to Scopus BioPharma Inc.	$ (2,431,393)	$ (4,642,908)
Net loss per common share attributable to Scopus BioPharma Inc.:
Net loss per common share attributable to Scopus BioPharma, Inc., Basic	$ (0.08)	$ (0.22)
Net loss per common share attributable to Scopus BioPharma, Inc., Diluted	$ (0.08)	$ (0.22)
Weighted-average common shares outstanding:
Weighted-average common shares outstanding, Basic	30,369,597	21,094,264
Weighted-average common shares outstanding, Diluted	30,369,597	21,094,264

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total Scopus BioPharma Inc. stockholders' equity (deficit)	Common Stock	Additional Paid-in Capital	Stock Subscriptions Receivable	Accumulated Deficit	Accumulated Other Comprehensive Loss	Noncontrolling Interest (Deficit)	Total
Balance at the beginning at Dec. 31, 2021		$ 21,094	$ 45,538,156		$ (41,455,148)	$ (86,653)		$ 4,017,449
Balance at the beginning (in shares) at Dec. 31, 2021		21,094,264
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense			95,028					95,028
Foreign currency translation adjustment						17,866		17,866
Net loss					(4,660,774)			(4,660,774)
Balance at the end at Mar. 31, 2022		$ 21,094	45,633,184		(46,115,922)	(68,787)		(530,431)
Balance at the end (in shares) at Mar. 31, 2022		21,094,264
Balance at the beginning at Dec. 31, 2022	$ (6,564,330)	$ 21,094	46,518,455	$ (33,950)	(53,064,975)	(4,954)	$ (497,839)	(7,062,169)
Balance at the beginning (in shares) at Dec. 31, 2022		21,094,264
Increase (Decrease) in Stockholders' Equity (Deficit)
Stock-based compensation expense	78,108		78,108					78,108
Proceeds from Duet Private Placement, net of transaction costs of $84,072	1,071,131		1,040,759	30,372			(35,228)	1,035,903
Proceeds from Scopus Private Placement	899,500	$ 18,490	906,010	(25,000)				$ 899,500
Proceeds from Scopus Private Placement (in shares)		18,490,000
Number of shares issued (in shares)								18,490,000
Foreign currency translation adjustment	18,429					18,429		$ 18,429
Net loss	(2,449,822)				(2,449,822)		(229,834)	(2,679,656)
Balance at the end at Mar. 31, 2023	$ (6,946,984)	$ 39,584	$ 48,543,332	$ (28,578)	$ (55,514,797)	$ 13,475	$ (762,901)	$ (7,709,885)
Balance at the end (in shares) at Mar. 31, 2023		39,584,264

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)	3 Months Ended
	Mar. 31, 2023 USD ($)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
Transaction costs	$ 84,072

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (2,679,656)	$ (4,660,774)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	231	609
Stock-based compensation expense	78,108	95,028
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	65,607	(389,066)
Accounts payable and accrued expenses	1,866,900	976,684
Other current liabilities	(91,046)
Net cash used in operating activities	(759,856)	(3,977,519)
Cash flows from investing activities:
Purchases of property and equipment		(1,552)
Cash flows from financing activities:
Proceeds from Duet Private Placement of common stock and Warrants, net of cash transaction costs of $49	1,119,926
Proceeds from Scopus Private Placement of common stock	899,500
Net cash provided by financing activities	2,019,426
Effects of changes in foreign currency exchange rates on cash	17,330	10,894
Net increase (decrease) in cash	1,276,900	(3,968,177)
Cash, beginning of period	124,575	7,942,971
Cash, end of period	1,401,475	$ 3,974,794
Non-cash financing activity:
Issuance costs included in accounts payable and accrued expenses	$ 84,023

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	3 Months Ended
	Mar. 31, 2023 USD ($)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Cash transaction costs	$ 49

Organization and Description of

Organization and Description of the Business	3 Months Ended
	Mar. 31, 2023
Organization and Description of the Business
Organization and Description of the Business	1. Organization and Description of the Business Nature of Operations Scopus BioPharma Inc. (“Scopus”) and its subsidiary, Vital Spark Inc. (“VSI”), are headquartered in New York, New York. Its other subsidiaries, Duet BioTherapeutics Inc. (“Duet”) (formerly Olimmune Inc.) and Scopus BioPharma Israel Ltd. (“SBI”), are headquartered in Los Angeles, California and Jerusalem, Israel, respectively. Scopus, VSI, Duet, and SBI are collectively referred to as the “Company.” The Company is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. Going Concern The Company is an early-stage company and has not generated revenues to date. As such, the Company is subject to all of the risks associated with early-stage companies. Since inception, the Company has incurred losses and negative cash flows from operating activities which have been funded from the issuance of common stock, convertible notes, warrants and additional investment options (“AIOs”). The Company does not expect to generate positive cash flows from operating activities for at least the next several years, if at all, until such time it completes the development of its drug candidates, including obtaining regulatory approvals, and anticipates incurring operating losses for the foreseeable future. The Company incurred a net loss of $2,679,656 for the three months ended March 31, 2023 and had an accumulated deficit of $55,514,797 as of March 31, 2023. The Company’s net cash used in operating activities was $759,856 for the three months ended March 31, 2023 and the working capital deficit totaled $7,711,919 as of March 31, 2023. Further, while the Company has raised significant cash proceeds from public offerings and private placements (see Notes 3 and 7), the Company still has significant obligations related to certain research and development acquisitions and agreements (see Note 5). The Company’s ability to fund its operations is dependent upon management’s plans, which include raising capital through issuances of debt and equity securities, securing research and development grants, and controlling the Company’s expenses. A failure to raise sufficient financing and/or control expenses, among other factors, will adversely impact the Company’s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. The Company’s results of operations and its ability to fund its operations may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond its control. The business could be impacted by, among other things, downturns in the financial markets or in economic conditions, inflation, increases in interest rates, the ongoing effects of the COVID-19 pandemic, including resurgences and the emergence of new variants, and geopolitical instability, such as the military conflict in the Ukraine. Accordingly, based on the considerations discussed above, management has concluded there is substantial doubt as to the Company’s ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. The Company’s condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities should the Company be unable to continue as a going concern. Trading Market for the Company’s Common Stock As previously disclosed on Form 8-K filed with the SEC on December 16, 2022, trading in the Company’s common stock on Nasdaq was suspended on December 19, 2022. Upon satisfaction of certain Nasdaq procedural requirements, formal delisting of the Company’s common stock occurred in March 2023. Upon the suspension of trading on Nasdaq in December 2022, the Company’s common stock commenced trading on the OTCQB. Trading in over-the-counter securities is subject to various regulatory requirements and constraints, which generally have an adverse effect on liquidity, which may, among other things, make it more difficult to buy and sell such securities and result in trading price inefficiency and volatility. The OTCQB requires, among other things, that companies be current on its filings and satisfy applicable requirements under the Securities Exchange Act of 1934. The OTCQB has additional requirements, including a minimum share price and unaffiliated share ownership. Failure to satisfy these and other requirements could result in the Company’s common stock no longer being eligible to trade on the OTCQB. COVID-19 Pandemic COVID-19 had a material adverse impact on the Company, including delays in drug development. As previously disclosed, the COVID-19 pandemic, including related constraints on mobility and travel, caused delays in enrollment in the investigator-sponsored clinical trial for our initial immuno-oncology drug candidate, for which the Company had previously received IND clearance from the FDA. Although in the United States the COVID-19 global pandemic emergency declarations are set to expire in May 2023, there may continue to be residual effects of COVID-19, especially as it relates to potential clinical trial participants who are predominately immunocompromised. There can be no assurance that a resurgence of COVID-19 will not occur and any such resurgence is likely to have a material adverse effect on drug development, which would have a material adverse effect on the Company and its financial condition. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has irrevocably elected to avail itself of this exemption from new or revised accounting standards, and, therefore, will not be subject to the same new or revised accounting standards as public companies that are not emerging growth companies. Basis of Presentation and Principles of Consolidation The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. In management’s opinion, the accompanying statements reflect adjustments necessary to present fairly the financial position, results of operations, and cash flows for those periods indicated, and contain adequate disclosure to make the information presented not misleading. Adjustments included herein are of a normal, recurring nature unless otherwise disclosed in the footnotes. All significant intercompany transactions have been eliminated upon consolidation. The accompanying condensed consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiaries including VSI and SBI and majority-owned subsidiary, Duet. The portion of Duet not owned by the Company is presented as a noncontrolling interest as of and during the periods consolidated. All significant intercompany accounts and transactions have been eliminated in consolidation. The financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 14, 2023 (the “2022 Form 10-K”). The accompanying balance sheet as of December 31, 2022 has been derived from the audited balance sheet as of December 31, 2022 contained in the Company's 2022 Form 10-K. Results of operations for interim periods are not necessarily indicative of the result of operations for a full year. Foreign Currency The functional currency of Scopus, VSI and Duet is the U.S. Dollar, and the functional currency of SBI is the Israeli New Shekel. All assets and liabilities of SBI are translated at the current exchange rate as of the end of the period and the related translation adjustments are recorded as a separate component of accumulated other comprehensive loss. Revenue and expenses are translated at average exchange rates in effect during the period. Foreign currency transaction gains and losses resulting from, or expected to result from, transactions denominated in a currency other than the functional currency are recognized in “General and administrative” expenses in the condensed consolidated statements of comprehensive loss. Comprehensive Income (Loss) Comprehensive income (loss) includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. Accumulated other comprehensive income (loss), net of tax, consists of foreign currency translation adjustment gains (losses) of $13,475 and ($4,954) as of March 31, 2023 and December 31, 2022, respectively. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates in these condensed consolidated financial statements include those related to the fair value of stock-based compensation, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets, and probability of meeting certain milestones. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from those estimates. Cash At times, the balance of the Company’s cash deposits may exceed federally insured limits, and there is no insurance on cash deposits within Israel. The Company has not experienced and does not anticipate any losses on deposits with commercial banks and financial institutions which exceed federally insured limits. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. The property and equipment balances as of March 31, 2023 and December 31, 2022 consist of computer equipment. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of 3 years. Depreciation expense for the three months ended March 31, 2023 and 2022 was $231 and $609, respectively. Research and Development Expenses Research and development expenses are expensed as incurred and consist principally of internal and external costs which includes the cost of patent licenses, contract research services, laboratory supplies, acquired in-process research and development, as well as development and manufacture of preclinical compounds and consumables for clinical trials and pre-clinical testing. Fair Value Measurement Certain assets and liabilities are carried at fair value in accordance with U.S. GAAP. Fair value is defined as the price which would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies, are as follows: Level 1 Valuations based on quoted prices for identical assets and liabilities in active markets. Level 2 Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets which are not active, or other inputs observable or can be corroborated by observable market data. Level 3 Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. As of March 31, 2023 and December 31, 2022, the carrying amounts of the Company’s cash, and accounts payable and accrued expenses approximate their respective fair values due to the short-term nature of these instruments. There were no assets or liabilities measured at fair value on a recurring or non-recurring basis at March 31, 2023 and December 31, 2022. Stock Subscriptions Receivable The stock subscriptions receivable balances as of March 31, 2023 and December 31, 2022 include cash to be received for shares of Class B common stock of Duet (“Duet Shares”), Series W Warrants of Duet (“Duet Warrants”), and shares of common stock of Scopus issued prior to the balance sheet date, in connection with the Duet Private Placement and Scopus Private Placement (see Note 3). Stock-Based Compensation The Company accounts for share-based payments in accordance with Accounting Standard Codification Topic 718, Compensation—Stock Compensation (“Topic 718”). Under Topic 718, the Company measures, and records compensation expense related to share-based payment awards (to employees and non-employees) based on the grant date fair value using the Black-Scholes option-pricing model. Forfeitures are recognized when they occur. The Company calculates the fair value of options granted using the Black-Scholes option-pricing model using the following assumptions: Expected Volatility – Due to the lack of substantial company-specific historical and implied volatility data of its common stock, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public companies. When selecting these companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company will continue to apply this process until sufficient amount of historical information regarding the volatility of its own stock price becomes available. Expected Term – The expected term of the Company’s options represents the period that the stock-based awards are expected to be outstanding. The Company has limited historical data upon which it can estimate the expected lives of the share-based payment awards and accordingly has used the simplified method allowable under SEC Staff Accounting Bulletin Topic 14 for employee holders and the contractual term for non-employee holders. Risk-Free Interest Rate – The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a term that is equal to the expected term of the options at the grant date. Dividend Yield – The Company has not declared or paid dividends to date and does not anticipate declaring dividends in the foreseeable future. As such, the dividend yield has been estimated to be zero. Noncontrolling Interest Noncontrolling interest represents the portion of net book value (deficit) in Duet that is not owned by Scopus and is reported as a component of stockholders’ equity (deficit) in Scopus’s condensed consolidated balance sheets (see Note 7). Net income (loss) is allocated to the noncontrolling interest based on the noncontrolling ownership percentage held in Duet. Net Loss Per Share Basic net loss per common share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the relevant period. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as dilutive net loss per share as the inclusion of the weighted-average number of all potential dilutive common shares, which consists of stock options, warrants and AIOs, would be anti-dilutive. The following table presents the weighted-average, potentially dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders, because their effect was anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2023 2022 Warrants ​ 2,579,078 ​ 23,458,418 Stock options ​ 772,500 ​ 849,283 Additional Investment Options (AIOs) ​ 3,225,000 ​ 3,225,000 Contingent consideration in common stock 1,266,666 1,266,666 Total 7,843,244 28,799,367 ​ Recent Accounting Pronouncements The Company, as an emerging growth company, has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of The Securities Act of 1933, for complying with new or revised accounting standards, which allows us to defer adoption of certain accounting standards until those standards would otherwise apply to private companies unless otherwise noted. Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Equity offerings

Equity offerings	3 Months Ended
	Mar. 31, 2023
Equity offerings
Equity offerings	3. Equity offerings During the first quarter of 2023, the Company raised an aggregate of approximately $924,500 from the issuance of common stock in a private placement at a price of $0.05 per share (the “Scopus Private Placement”), of which $25,000 is included in stock subscriptions receivable as of March 31, 2023 (see Note 7). During the fourth quarter of 2022, Duet raised $276,065 from third-party investors from the sale of Duet Shares and Duet Warrants at prices of $2.50 per share and $0.05 per warrant, respectively (the “Duet Private Placement”). The Duet Warrants are exercisable at $2.50 per share of Duet’s Class B Common Stock beginning on the date that is one year after the date that the shares of Duet’s Class B Common Stock are first traded or quoted on a public trading market (“Duet Class B Shares Initial Trading Date”) and expiring five years from the Duet Class B Shares Initial Trading Date. During the first quarter of 2023, in connection with the Duet Private Placement, Duet raised an additional $1,089,603. Of the total aggregate proceeds of $1,365,668 from the Duet Private Placement through March 31, 2023, $3,578 and $33,950 were included in stock subscriptions receivable in the accompanying condensed consolidated balance sheets as of March 31, 2023 and December 31, 2022, respectively. ​

Accounts payable and accrued ex

Accounts payable and accrued expenses	3 Months Ended
	Mar. 31, 2023
Accounts payable and accrued expenses
Accounts payable and accrued expenses	4. Accounts payable and accrued expenses Accounts payable and accrued expenses consist of the following as of: ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, December 31, ​ ​ 2023 ​ 2022 Professional fees ​ $ 5,149,587 ​ $ 4,748,128 Research and development expenses ​ ​ 3,538,191 ​ ​ 2,028,923 Management service fees and expenses (related parties) ​ 273,530 ​ 249,236 Other accounts payable and accrued expenses ​ 190,442 ​ 175,639 Total accounts payable and accrued expenses ​ $ 9,151,750 ​ $ 7,201,926 ​

Research and Development Agreem

Research and Development Agreements	3 Months Ended
	Mar. 31, 2023
Research and Development Agreements
Research and Development Agreements	5. Research and Development Agreements Agreement Related to Intellectual Property Rights In July 2017, VSI, as “Licensee,” entered into a Patent License Agreement (the “Patent License Agreement”) with the U.S. Department of Health and Human Services, as represented by the National Institute on Alcohol Abuse and Alcoholism (“NIAAA”) and the National Institute on Drug Abuse (“NIDA”) of the National Institutes of Health (“NIH”), (collectively “Licensor”). In the course of conducting biomedical and behavioral research, the Licensor developed inventions that may have commercial applicability. The Company acquired commercialization rights to certain inventions in order to develop processes, methods, or marketable products for public use and benefit. Patent fee reimbursement under the Patent License Agreement was $0 and $5,017 for the three months ended March 31, 2023 and 2022, respectively. These costs are included in “Research and development” expenses in the accompanying condensed consolidated statements of comprehensive loss. Pursuant to the terms of the Patent License Agreement, VSI was required to make minimum annual royalty payments on January 1 of each calendar year, which shall be credited against any earned royalties due for sales made in that year, throughout the term of the Patent License Agreement. For the three months ended March 31, 2023 and 2022, $0 and $6,250 minimum royalty payments, respectively, were recognized in each period in “Research and development” expenses in the accompanying condensed consolidated statements of comprehensive loss. The Patent License Agreement also provides for payments from VSI to the Licensor upon the achievement of certain product development and regulatory clearance milestones, as well as royalty payments on net sales upon the commercialization of products developed utilizing the licensed patents (see below). Through March 31, 2023, the Licensor has not achieved any milestones and therefore VSI has not made any milestone payments. VSI is obligated to pay earned royalties based on a percentage of net sales, as defined in the Patent License Agreement, of licensed product throughout the term of the Patent License Agreement. Since April 18, 2017 (inception) through March 31, 2023, there have been no sales of licensed products. In addition, VSI is also obligated to pay the Licensor additional sublicensing royalties on the fair market value of any consideration received for granting each sublicense. Through March 31, 2023, VSI has not entered into any sublicensing agreements and therefore no sublicensing consideration has been paid to Licensor. The Company’s rights under its license with the NIH may overlap with rights which may have been granted to another company. The Company has been in communication with the NIH seeking clarification as to each company’s rights. The Company has also had, from time to time, discussions with such other company to explore possible collaborations. The Company has been unable to enter into any such arrangements. Notwithstanding the Company’s attempts to engage the NIH to clarify these overlapping rights, the NIH has disregarded such requests. By email dated August 15, 2022, the NIH purported to terminate the Company’s rights. The Company rejected the NIH’s purported action and intends to further seek to engage with the NIH in an attempt to protect and clarify its rights. Memorandums of Understanding Effective July 28, 2018, SBI entered into two Memorandums of Understanding (“MOUs”) with Yissum Research Development Company (“Yissum”) of the Hebrew University of Jerusalem Ltd. (“Hebrew University”). Research under the Yissum MOUs was completed in December 2019 and March 2020, respectively, resulting in the license agreements below. Effective March 5, 2019, the Company entered in a license agreement with Yissum with respect to the results of the research relating to the combination of cannabidiol with approved anesthetics as a potential treatment for the management of pain. Under the license agreement, the Company is obligated to pay earned royalties based on a percentage of net sales, as defined in the license agreement, including net sales generated from sub-licensees. In addition, the Company will be obligated to make payments upon the achievement of certain clinical development and product approval milestones. From March 5, 2019 through March 31, 2023, there have been no sales of licensed products by the Company nor has the Company entered into any sub-licensing agreements. Further, none of the milestones in the agreement have been reached and therefore as of March 31, 2023, there is no obligation to make any milestone payments. Effective August 8, 2019, the Company entered into a second license agreement with Yissum with respect to the research results relating to the synthesis of novel cannabinoid dual-action compounds and novel chemical derivatives of cannabigerol and tetrahydrocannabivarin. Under this license agreement, the Company is required to pay earned royalties based upon a percentage of net sales at one percentage for regulated products and a lesser percentage for non-regulated products. The Company is obligated to pay development milestone payments tied to regulated products totaling $1,225,000 in the aggregate and $100,000 for non-regulated products in the aggregate. None of the milestones in the agreement have been reached and therefore as of March 31, 2023 there is no obligation to make any milestone payments. CpG-STAT3siRNA (DUET-01) Agreements In June 2020, the Company entered into an exclusive, worldwide license agreement with City of Hope (“COH”) relating to DUET-01 (the “DUET-01 Exclusive License Agreement”). In addition to the DUET-01 Exclusive License Agreement, the Company also entered into a Sponsored Research Agreement (the “SRA”) relating to on-going research and development activities in collaboration with COH relating to DUET-01. The Company obtained the right to negotiate the DUET-01 Exclusive License Agreement with COH as part of the Bioscience Oncology Pty Ltd acquisition in June 2020. The Company incurred license maintenance fees in relation to the DUET-01 Exclusive License Agreement of $7,500 during each of the three months ended March 31, 2023 and 2022. In September 2022, the SRA was extended until September 2023 with no additional costs to the Company. Under the terms of the DUET-01 Exclusive License Agreement, the Company is obligated to pay earned royalties based on a percentage of net sales, as defined in the DUET-01 Exclusive License Agreement, including net sales generated from sub-licensees. In addition, the Company is obligated to make payments in cash upon the achievement of certain clinical development and product approval milestones totaling $3,525,000 in the aggregate. None of the milestones in the DUET-01 Exclusive License Agreement have been reached and therefore as of March 31, 2023, there is no obligation to make any milestone payments. Pursuant to the terms of the SRA, the Company has committed to fund research and development at COH for two years in accordance with a predetermined funding schedule. Total expenses incurred in connection with the SRA were $0 and $62,500 for the three months ended March 31, 2023 and 2022, respectively. These expenses are included in “Research and development” expenses in the accompanying condensed consolidated statements of comprehensive loss. Further, the Company incurred costs of $44,000 and $43,433 during the three months ended March 31, 2023 and 2022, respectively, pursuant to a clinical research support agreement (the “CRSA”) relating to a Phase 1 clinical trial for DUET-01 to be conducted at COH. These expenses are included in “Research and development” expenses in the accompanying condensed consolidated statements of comprehensive loss. On April 7, 2022, the Company entered into a sponsored research agreement (the “Kortylewski SRA”) with COH for research to be conducted by Marcin Kortylewski, Ph.D., a Co-Founder and Senior Advisor of Duet and Professor in the Department of Immuno-Oncology at COH. Pursuant to the Kortylewski SRA, Dr. Kortylewski and his lab are evaluating novel chemical structures and formulations to increase the stability of siRNA-based molecules to enable systemic delivery. The research under the Kortylewski SRA is conducted over a two-year period at a cost of approximately $200,000 per year. The Company incurred $50,722 and $0 during the three months ended March 31, 2023 and 2022, respectively, related to the Kortylewski SRA,and is included in “Research and development” expenses in the accompanying condensed consolidated statements of comprehensive loss. Duet (DUET-02 and DUET-03) License Agreements On June 25, 2021, the Company entered into two exclusive, worldwide license agreements with COH relating to Duet’s drug candidates. The Company obtained the rights to negotiate the CpG-STAT3ASO Patent Rights License Agreement and the CpG-STAT3decoy Patent Rights License Agreement (together, the “Duet License Agreements”) with COH as part of the Duet acquisition in June 2021. Under the terms of the Duet License Agreements, the Company is obligated to pay earned royalties based on a percentage of net sales, as defined in the Duet License Agreements, including net sales generated from sub-licensees. The Company incurred license fees of $16,730 and $12,500 in connection with the Duet License Agreements during the three months ended March 31, 2023 and 2022, respectively. License fees related to the Duet License Agreements of $249,807 and $233,076 were included in accounts payable and accrued expenses at March 31, 2023 and December 31, 2022, respectively. On April 19, 2022, the Company entered into an amendment to the DUET-02 Patent Rights License Agreement with COH to secure a non-exclusive royalty bearing right and license to use and make derivative works of certain technical information and know how related to DUET-02. In connection with the amendment, the Company agreed to make a one-time non-refundable license fee payment of $25,000 to COH within five days of the effective date of the amendment. In addition, the Company is obligated to make payments in cash upon the achievement of certain clinical development and product approval milestones totaling $6,750,000 for each license

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies
Commitments and Contingencies	6. Commitments and Contingencies Research and Development Agreements The Company has entered into various research and development agreements which require the Company to provide certain funding and support. See Note 5 for further information regarding these agreements. Legal Proceedings The Company continues to be a party in several litigation matters initiated by or against certain adverse parties and certain of their affiliates and/or related parties (the “Adverse Parties”) who are stockholders of the Company and certain of whom are also former officers and/or directors of the Company. As previously disclosed, one of such Adverse Parties initiated litigation with respect to a dispute about ownership of certain shares and various other matters. Most recently, a trial date was scheduled for May 25, 2023, which was subsequently postponed. It is currently uncertain as to when any trial date may be rescheduled. Such Adverse Parties also filed a stockholder derivative complaint, purportedly on behalf of the Company. The Company filed a motion to dismiss this stockholder derivative complaint in November 2021. In March 2022, the Delaware Court of Chancery (“Chancery Court”) dismissed such complaint. One of the Adverse Parties also initiated an action in the Supreme Court of the State of New York (the “New York Court”) alleging, among other things, that he was wrongfully terminated by the Company. In March 2023, the New York Court dismissed all of the claims in such action other than the wrongful termination claim. Due to the factual nature of such claim, it remains subject to further proceedings. The status and timing of the remaining litigation matters are uncertain. The outcome relating to any such matters, and litigation generally, are highly unpredictable and the costs of litigation, including legal fees, costs and expenses, and the possible liabilities, including monetary damages, to which the Company could become subject could be significant. Any such liabilities could have a material adverse effect on the Company. The Company’s existing capital resources will not be sufficient to implement its business plan, including the development of its drug candidates, especially if the Company continues to be subject to or pursuing ongoing litigation. The Company requires additional financing and there can be no assurance that any such financing will be available on satisfactory terms, or at all. Failure to obtain additional financing will have a material adverse effect on the Company.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity
Stockholders' Equity	7. Stockholders’ Equity Preferred Stock The Company is authorized to issue 20,000,000 shares of preferred stock with a par value of $0.001 per share with such designation, rights and preferences as may be determined from time-to-time by the Company’s board of directors. Authority is expressly vested in the board of directors to authorize the issuance of one or more series of preferred stock. All 20,000,000 shares remained unissued as of March 31, 2023 and December 31, 2022. Common Stock The Company is authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share. The number of authorized shares of common stock may be increased or decreased (but not below the number of shares of common stock then outstanding) by an affirmative vote of the holders of a majority of the common stock. The powers, preferences, and rights of the holders of the common stock are junior to the preferred stock and are subject to all the powers, rights, privileges, preferences, and priorities of the preferred stock. The holder of each share of common stock shall have the right to one vote per share. Each holder of common stock shall be entitled to receive dividends and distributions (whether payable in cash or otherwise) as declared by the board of directors of the Company, subject to the rights of any class of preferred stock outstanding. In the event of any liquidation, dissolution or winding-up of the Company (whether voluntary or involuntary), the assets available for distribution to holders of common stock will be in equal amounts per share. During the first quarter of 2023, Scopus raised an aggregate of approximately $924,500, of which $25,000 is included in stock subscriptions receivable as of March 31, 2023, from the sale of 18,490,000 shares of common stock at a price of $0.05 per share. Warrants Each W Warrant is exercisable for one Series B Unit (“B Unit”). Each B Unit consists of one share of common stock and one Series Z Warrant (“Z Warrant”). Each Z Warrant is exercisable for one share of common stock. The exercise price of the W Warrant is $4.00, and the exercise price of the Z Warrant is $5.00. The W Warrants became exercisable on October 1, 2021 and the Z Warrants became exercisable on July 1, 2022. The W Warrants and Z Warrants expire on September 30, 2026 and June 30, 2027, respectively, unless previously exercised. In October 2022, in connection with a recapitalization of Duet, Scopus entered into exchange agreements with the holders of 10,439,670 W Warrants, exercisable into an aggregate of 20,879,340 shares of Scopus common stock, pursuant to which such W Warrants were exchanged for 1,043,989 Duet Shares previously owned by Scopus (the “Warrant Exchanges”). Each W Warrant was exchanged for one Subsequent to the Warrant Exchanges, Scopus held an approximately 90% financial interest in Duet. As such, the Warrant Exchanges resulted in a deficit to the noncontrolling interest account of $379,522, which represents the portion of Duet’s noncontrolling stockholders’ interest in the negative book value of Duet at the date of the Warrant Exchanges. As of March 31, 2023, 1,414,539 Scopus warrants were outstanding and exercisable at a weighted-average exercise price of $3.56. As of March 31, 2023, the remaining contractual term of the outstanding warrants was 3.3 years. Of the 1,414,539 Scopus warrants outstanding as of March 31, 2023, 1,164,539 are W Warrants and 250,000 are warrants exercisable into one share of common stock each, at an exercise price of $1.50 per warrant, with an expiration date of October 3, 2025. AIOs As of March 31, 2023, the Company had outstanding Series A Additional Investment Options (the “Series A AIOs”) to purchase 1,500,000 shares of Common Stock and Series B Additional Investment Options (the “Series B AIOs,” together with the Series A AIOs, the “AIOs”) to purchase 1,500,000 shares of common stock, at a purchase price of $3.25 per share. The Series A AIOs are exercisable immediately and have a term of five years starting on January 18, 2022 and have an exercise price of $3.125 per share. The Series B AIOs became exercisable upon effectiveness of that certain Registration Statement on Form S-3 (File No 333-261991), which was declared effective by the SEC on January 18, 2022, and have a term of five years starting on January 18, 2022 and have an exercise price of $3.125 per share. In addition, as of March 31, 2023, certain AIOs issued to a placement agent during 2021 were outstanding (the “Placement Agent AIOs”), which allow the placement agent to purchase up to 225,000 shares of common stock. The Placement Agent AIOs have an exercise price equal to $4.0625, with a term of five years following January 18, 2022. As of March 31, 2022, no AIOs or Placement Agent AIOs have been exercised or forfeited. As of March 31, 2023, an aggregate of 3,225,000 AIOs and Placement Agent AIOs were outstanding at a weighted-average exercise price of $3.19. As of March 31, 2023, the remaining contractual term of the outstanding AIOs was 3.6 years. Contingent Common Stock As a result of the Company’s acquisition of Bioscience Oncology in June 2021, the previous shareholders of Bioscience Oncology are eligible to receive remaining contingent consideration of up to approximately 1.3 million shares of common stock upon the achievement of a specified milestone, which will be recorded when it is determined the corresponding milestone is probable to be achieved. Noncontrolling Interest In connection with the Warrant Exchanges, Duet’s certificate of incorporation was amended and restated to authorize (i) an additional 50,000,000 shares of capital stock and (ii) the redesignation of its common stock to include shares of Class A common stock (“Class A Common Stock”) and shares of Class B common stock (“Class B Common Stock”). The Class A Common Stock and Class B Common Stock are identical, except that the holders of Class A Common Stock are entitled to ten votes per share and holders of Class B Shares are entitled to one vote per share. All of the outstanding shares of Class A Common Stock are owned by Scopus. In addition, each share of Class A Common Stock is convertible, at the option of Scopus in its sole discretion, at any time into one share of Class B Common Stock. Each share of Class A Common Stock is automatically convertible into one share of Class B Common Stock if it is held by anyone other than Scopus or a permitted transferee. During the fourth quarter of 2022, Duet raised $276,065 from third-party investors in connection with the Duet Private Placement. During the first quarter of 2023, in connection with the Duet Private Placement, Duet raised an additional $1,089,603. The related issuance costs were approximately $84,072. Of the total aggregate proceeds of $1,365,668 from the Duet Private Placement through March 31, 2023, $3,578 and $33,950 were included in stock subscriptions receivable in the accompanying condensed consolidated balance sheets as of March 31, 2023 and December 31, 2022, respectively. During the three months ended March 31, 2023, the Duet Private Placement resulted in an increase to the deficit of the noncontrolling interest of $35,228, which represents the additional portion of Duet’s noncontrolling stockholders’ interest in the negative book value of Duet at the dates of issuances of the Duet Shares. After giving effect to the Warrant Exchanges and the Duet Private Placement, Scopus continues to be the controlling stockholder of Duet with voting control of approximately 98%.

Stock Options

Stock Options	3 Months Ended
	Mar. 31, 2023
Stock Options
Stock Options	8. Stock Options Effective September 24, 2018, the Company approved the Scopus BioPharma Inc. 2018 Equity Incentive Plan (the “Plan”), and reserved 1,000,000 shares of the Company’s common stock, such amount subsequently being increased to 2,400,000 shares, for issuance under the Plan. As of March 31, 2023, there were 1,800,000 shares authorized for issuance under the Plan, subject to the Company having sufficient authorized shares for any such issuances. The stock options shall be granted at an exercise price per share equal to at least the fair market value of the shares of common stock on the date of grant and generally vest over a three-year period. Stock option activity is summarized as follows for the three months ended March 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ average ​ ​ ​ ​ average ​ Remaining ​ ​ Options ​ Exercise Price ​ Contractual Life Outstanding at December 31, 2022 ​ 772,500 ​ $ 5.15 ​ ​ 4.20 Granted ​ — ​ ​ — ​ ​ — Exercised — ​ — ​ — Forfeited — ​ — ​ — Outstanding at March 31, 2023 772,500 ​ $ 5.15 ​ ​ 3.95 Vested and exercisable at March 31, 2023 701,801 ​ $ 5.11 ​ ​ 4.07 Unvested at March 31, 2023 70,699 ​ $ 5.50 ​ ​ 2.71 ​ Included in the table above are 172,500 options issued to the underwriters outside of the Plan in connection with the Company’s public offerings during 2021. Stock-based compensation expense associated with the vesting of options was $78,108 and $95,028 for the three months ended March 31, 2023 and 2022, respectively. This cost is included in “General and administrative” expenses in the accompanying condensed consolidated statements of comprehensive loss. As of March 31, 2023, total unrecognized stock-based compensation expense was $220,887 and is expected to be recognized over the remaining weighted-average contractual vesting term of 0.7 years.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions
Related Party Transactions	9. Related Party Transactions The Company has a management services agreement, as amended, with Portfolio Services, an affiliated entity, to provide management services to the Company including, without limitation, financial and accounting resources, general business development, corporate development, corporate governance, marketing strategy, strategic development and planning, coordination with service providers and other services as agreed upon between the parties. The Company pays Portfolio Services a monthly management services fee plus related expense reimbursement and provision of office space and facilities. The monthly management services fee and monthly facilities fee are $50,000 and $3,000, respectively. During each of the three months ended March 31, 2023 and 2022, the Company incurred expenses of $159,000 of management services fees related to the management services agreement. The costs are included in “General and administrative” expenses in the accompanying condensed consolidated statements of comprehensive loss. Amounts payable to Portfolio Services as of March 31, 2023 and December 31, 2022 were $75,000 and $50,706, respectively. Pursuant to a management services agreement with Clil Medical Ltd. (“Clil”), an affiliate of a co-founder and former director of the Company, such individual was obligated to provide executive and other management services to the Company. This management services agreement was terminated in June 2020 and, concurrently, such individual resigned as a director of the Company, but continued to serve in various other capacities for the Company and its subsidiaries. Subsequently, such individual submitted resignations to the Company and its subsidiaries. The Company and such individual do not agree on various matters, including obligations under the applicable management services agreement, both prior and subsequent to its termination. The amounts for the services provided through the termination date were fully accrued for as of March 31, 2023 and December 31, 2022. No expenses were incurred under this management services agreement during either of the three months ended March 31, 2023 and 2022. As of March 31, 2023 and December 31, 2022, the total amount due to Clil was $198,530, and is included in “Accounts payable and accrued expenses” on the accompanying condensed consolidated balance sheets. On September 26, 2021, the Board approved an indemnification agreement (the “Indemnification Agreement”), pursuant to which the Company has agreed to indemnify each of the Executive Committee Directors, the employees of HCFP, and certain affiliates and related entities (collectively, the “Indemnified Parties”) from and against any losses, claims, damages or liabilities, including reasonable attorney’s fees, suffered or incurred by the Indemnified Parties in connection with any disputes, litigation or threatened litigation (whether existing prior to or commencing after the date of the Indemnification Agreement) involving certain current or former executives and directors of the Company and arising or resulting from any Indemnified Party’s affiliation or involvement with the Company, including in connection with the provision of additional services beyond those initially contemplated under the Portfolio Services management services agreement. The Indemnification Agreement also provides that the Company will advance expenses to any Indemnified Party, including legal fees, incurred by such Indemnified Party in connection with any litigation or proceeding to which such Indemnified Party is entitled to indemnification under the Indemnification Agreement. The Company incurred $0 and $16,585 in legal fees and other expenses in connection with this Indemnification Agreement for the three months ended March 31, 2023 and 2022, respectively. ​

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Taxes
Income Taxes	10. Income Taxes The Company did not provide for any income taxes for the three months ended March 31, 2023 and 2022. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is not more likely than not that the Company will realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of March 31, 2023 and December 31, 2022. Management reevaluates the positive and negative evidence at each reporting period.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events
Subsequent Events	11. Subsequent Events Since the commencement of their respective private placements and as of May 8, 2023, Scopus and Duet raised aggregate gross proceeds of approximately $2.3 million on a consolidated basis in concurrent financings resulting from the sale of shares of Scopus common stock, Duet Shares, and Duet Warrants to third-party investors (Note 7). Shares of Scopus common stock were sold at a price of $0.05 per share and the Duet Shares and Duet Warrants were sold on the same terms as disclosed in Note 7. In April 2023, Scopus purchased 3,000,000 Duet Warrants identical to and at the purchase price for the Duet Warrants issued in the Duet Private Placement. The purchase price for such warrants was made through a reduction in the intercompany advances made by Scopus to Duet.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Summary of Significant Accounting Policies
COVID 19 Pandemic	COVID-19 Pandemic COVID-19 had a material adverse impact on the Company, including delays in drug development. As previously disclosed, the COVID-19 pandemic, including related constraints on mobility and travel, caused delays in enrollment in the investigator-sponsored clinical trial for our initial immuno-oncology drug candidate, for which the Company had previously received IND clearance from the FDA. Although in the United States the COVID-19 global pandemic emergency declarations are set to expire in May 2023, there may continue to be residual effects of COVID-19, especially as it relates to potential clinical trial participants who are predominately immunocompromised. There can be no assurance that a resurgence of COVID-19 will not occur and any such resurgence is likely to have a material adverse effect on drug development, which would have a material adverse effect on the Company and its financial condition.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. In management’s opinion, the accompanying statements reflect adjustments necessary to present fairly the financial position, results of operations, and cash flows for those periods indicated, and contain adequate disclosure to make the information presented not misleading. Adjustments included herein are of a normal, recurring nature unless otherwise disclosed in the footnotes. All significant intercompany transactions have been eliminated upon consolidation. The accompanying condensed consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiaries including VSI and SBI and majority-owned subsidiary, Duet. The portion of Duet not owned by the Company is presented as a noncontrolling interest as of and during the periods consolidated. All significant intercompany accounts and transactions have been eliminated in consolidation. The financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 14, 2023 (the “2022 Form 10-K”). The accompanying balance sheet as of December 31, 2022 has been derived from the audited balance sheet as of December 31, 2022 contained in the Company's 2022 Form 10-K. Results of operations for interim periods are not necessarily indicative of the result of operations for a full year.
Foreign Currency	Foreign Currency The functional currency of Scopus, VSI and Duet is the U.S. Dollar, and the functional currency of SBI is the Israeli New Shekel. All assets and liabilities of SBI are translated at the current exchange rate as of the end of the period and the related translation adjustments are recorded as a separate component of accumulated other comprehensive loss. Revenue and expenses are translated at average exchange rates in effect during the period. Foreign currency transaction gains and losses resulting from, or expected to result from, transactions denominated in a currency other than the functional currency are recognized in “General and administrative” expenses in the condensed consolidated statements of comprehensive loss.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. Accumulated other comprehensive income (loss), net of tax, consists of foreign currency translation adjustment gains (losses) of $13,475 and ($4,954) as of March 31, 2023 and December 31, 2022, respectively.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates in these condensed consolidated financial statements include those related to the fair value of stock-based compensation, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets, and probability of meeting certain milestones. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from those estimates.
Cash	Cash At times, the balance of the Company’s cash deposits may exceed federally insured limits, and there is no insurance on cash deposits within Israel. The Company has not experienced and does not anticipate any losses on deposits with commercial banks and financial institutions which exceed federally insured limits.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. The property and equipment balances as of March 31, 2023 and December 31, 2022 consist of computer equipment. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of 3 years. Depreciation expense for the three months ended March 31, 2023 and 2022 was $231 and $609, respectively.
Research and Development Expenses	Research and Development Expenses Research and development expenses are expensed as incurred and consist principally of internal and external costs which includes the cost of patent licenses, contract research services, laboratory supplies, acquired in-process research and development, as well as development and manufacture of preclinical compounds and consumables for clinical trials and pre-clinical testing.
Fair Value Measurement	Fair Value Measurement Certain assets and liabilities are carried at fair value in accordance with U.S. GAAP. Fair value is defined as the price which would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy which prioritizes the inputs used in the valuation methodologies, are as follows: Level 1 Valuations based on quoted prices for identical assets and liabilities in active markets. Level 2 Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets which are not active, or other inputs observable or can be corroborated by observable market data. Level 3 Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. As of March 31, 2023 and December 31, 2022, the carrying amounts of the Company’s cash, and accounts payable and accrued expenses approximate their respective fair values due to the short-term nature of these instruments. There were no assets or liabilities measured at fair value on a recurring or non-recurring basis at March 31, 2023 and December 31, 2022.
Stock Subscriptions Receivable	Stock Subscriptions Receivable The stock subscriptions receivable balances as of March 31, 2023 and December 31, 2022 include cash to be received for shares of Class B common stock of Duet (“Duet Shares”), Series W Warrants of Duet (“Duet Warrants”), and shares of common stock of Scopus issued prior to the balance sheet date, in connection with the Duet Private Placement and Scopus Private Placement (see Note 3).
Stock-Based Compensation	Stock-Based Compensation The Company accounts for share-based payments in accordance with Accounting Standard Codification Topic 718, Compensation—Stock Compensation (“Topic 718”). Under Topic 718, the Company measures, and records compensation expense related to share-based payment awards (to employees and non-employees) based on the grant date fair value using the Black-Scholes option-pricing model. Forfeitures are recognized when they occur. The Company calculates the fair value of options granted using the Black-Scholes option-pricing model using the following assumptions: Expected Volatility – Due to the lack of substantial company-specific historical and implied volatility data of its common stock, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public companies. When selecting these companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected term of the stock-based awards. The Company will continue to apply this process until sufficient amount of historical information regarding the volatility of its own stock price becomes available. Expected Term – The expected term of the Company’s options represents the period that the stock-based awards are expected to be outstanding. The Company has limited historical data upon which it can estimate the expected lives of the share-based payment awards and accordingly has used the simplified method allowable under SEC Staff Accounting Bulletin Topic 14 for employee holders and the contractual term for non-employee holders. Risk-Free Interest Rate – The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a term that is equal to the expected term of the options at the grant date. Dividend Yield – The Company has not declared or paid dividends to date and does not anticipate declaring dividends in the foreseeable future. As such, the dividend yield has been estimated to be zero.
Noncontrolling Interest	Noncontrolling Interest Noncontrolling interest represents the portion of net book value (deficit) in Duet that is not owned by Scopus and is reported as a component of stockholders’ equity (deficit) in Scopus’s condensed consolidated balance sheets (see Note 7). Net income (loss) is allocated to the noncontrolling interest based on the noncontrolling ownership percentage held in Duet.
Net Loss Per Share	Net Loss Per Share Basic net loss per common share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the relevant period. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as dilutive net loss per share as the inclusion of the weighted-average number of all potential dilutive common shares, which consists of stock options, warrants and AIOs, would be anti-dilutive. The following table presents the weighted-average, potentially dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders, because their effect was anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2023 2022 Warrants ​ 2,579,078 ​ 23,458,418 Stock options ​ 772,500 ​ 849,283 Additional Investment Options (AIOs) ​ 3,225,000 ​ 3,225,000 Contingent consideration in common stock 1,266,666 1,266,666 Total 7,843,244 28,799,367 ​
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company, as an emerging growth company, has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of The Securities Act of 1933, for complying with new or revised accounting standards, which allows us to defer adoption of certain accounting standards until those standards would otherwise apply to private companies unless otherwise noted. Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Summary of Significant Accounting Policies
Schedule of weighted-average, potentially dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders	​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2023 2022 Warrants ​ 2,579,078 ​ 23,458,418 Stock options ​ 772,500 ​ 849,283 Additional Investment Options (AIOs) ​ 3,225,000 ​ 3,225,000 Contingent consideration in common stock 1,266,666 1,266,666 Total 7,843,244 28,799,367 ​

Accounts payable and accrued _2

Accounts payable and accrued expenses (Tables)	3 Months Ended
	Mar. 31, 2023
Accounts payable and accrued expenses
Schedule of accounts payable and accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, December 31, ​ ​ 2023 ​ 2022 Professional fees ​ $ 5,149,587 ​ $ 4,748,128 Research and development expenses ​ ​ 3,538,191 ​ ​ 2,028,923 Management service fees and expenses (related parties) ​ 273,530 ​ 249,236 Other accounts payable and accrued expenses ​ 190,442 ​ 175,639 Total accounts payable and accrued expenses ​ $ 9,151,750 ​ $ 7,201,926

Stock Options (Tables)

Stock Options (Tables)	3 Months Ended
	Mar. 31, 2023
Stock Options
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ Weighted- ​ average ​ ​ ​ ​ average ​ Remaining ​ ​ Options ​ Exercise Price ​ Contractual Life Outstanding at December 31, 2022 ​ 772,500 ​ $ 5.15 ​ ​ 4.20 Granted ​ — ​ ​ — ​ ​ — Exercised — ​ — ​ — Forfeited — ​ — ​ — Outstanding at March 31, 2023 772,500 ​ $ 5.15 ​ ​ 3.95 Vested and exercisable at March 31, 2023 701,801 ​ $ 5.11 ​ ​ 4.07 Unvested at March 31, 2023 70,699 ​ $ 5.50 ​ ​ 2.71 ​

Organization and Description _2

Organization and Description of the Business - Going concern (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Organization and Description of the Business
Net loss	$ 2,679,656	$ 4,660,774
Accumulated deficit	55,514,797		$ 53,064,975
Net cash used in operating activities	759,856	$ 3,977,519
Working capital deficit	$ (7,711,919)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Oct. 31, 2022
Summary of Significant Accounting Policies
Accumulated other comprehensive loss, net of tax	$ 13,475		$ (4,954)
Estimated Useful Life of Computer equipment	3 years
Depreciation expense	$ 231	$ 609
Duet
Summary of Significant Accounting Policies
Ownership percentage in Duet	98%			90%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Weighted average potentially dilutive shares (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Summary of Significant Accounting Policies
Total	7,843,244	28,799,367
Warrants
Summary of Significant Accounting Policies
Total	2,579,078	23,458,418
Stock options
Summary of Significant Accounting Policies
Total	772,500	849,283
Additional Investment Options (AIOs)
Summary of Significant Accounting Policies
Total	3,225,000	3,225,000
Contingent consideration in common stock
Summary of Significant Accounting Policies
Total	1,266,666	1,266,666

Equity offerings (Details)

Equity offerings (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Jan. 18, 2022
Equity offerings
Proceeds from issuance of warrants and shares	$ 899,500
Placement Agent
Equity offerings
Exercise price			$ 4.0625
Exercisable term		5 years
Series A Additional Investment Options
Equity offerings
Exercise price			3.125
Series B Additional Investment Options
Equity offerings
Exercise price			$ 3.125
Private placement
Equity offerings
Offering price (per share)	$ 0.05
Stock subscription receivable	$ 25,000
Proceeds from issuance of warrants and shares	924,500
Duet Private Placement
Equity offerings
Offering price (per share)		$ 2.50
Stock subscription receivable	3,578	$ 33,950
Additional proceeds from issuance of warrants and shares	1,089,603
Proceeds from issuance of warrants and shares	$ 1,365,668	$ 276,065
Price per warrant		$ 0.05
Exercise price		$ 2.50

Accounts payable and accrued _3

Accounts payable and accrued expenses (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Accounts payable and accrued expenses
Professional fees	$ 5,149,587	$ 4,748,128
Research and development expenses	3,538,191	2,028,923
Management service fees and expenses (related parties)	273,530	249,236
Other accounts payable and accrued expenses	190,442	175,639
Total accounts payable and accrued expenses	$ 9,151,750	$ 7,201,926

Research and Development Agre_2

Research and Development Agreements - Agreement Related to Intellectual Property Rights (Details) - Patent License Agreement - Licensor - VSI - USD ($)		3 Months Ended
	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Research and development arrangements
Fee incurred		$ 0	$ 5,017
Sales of licensed products	$ 0
Sublicensing consideration paid		0
Research and development
Research and development arrangements
Minimum annual royalty payments		$ 0	$ 6,250

Research and Development Agre_3

Research and Development Agreements - Memorandums of Understanding (Details) - SBI - Yissum Research Development Company [Member]	Mar. 31, 2023 USD ($)	Aug. 08, 2019 USD ($)	Jul. 28, 2018 item
Memorandums of Understanding
Research and development arrangements
Number of memorandums | item			2
Milestone payments obligation	$ 0
Development milestone payments tied to regulated products		$ 1,225,000
Development milestone payments tied to non-regulated products		$ 100,000
License agreement, one
Research and development arrangements
Sales of licensed products	0
License agreement, two
Research and development arrangements
Milestone payments obligation	$ 0
Percentage of net sales for regulated products		1%

Research and Development Agre_4

Research and Development Agreements - City of Hope License Agreement and Sponsored Research Agreement (Details)				1 Months Ended		3 Months Ended
	Apr. 19, 2022 USD ($)	Apr. 07, 2022 USD ($)	Jun. 25, 2021 USD ($) item	Sep. 30, 2022 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Research and development arrangements
Research and development expense relating to the phase 1 clinical trail		$ 200,000
City of Hope License Agreement
Research and development arrangements
Development and product approval milestones					$ 3,525,000
Duet License Agreements
Research and development arrangements
Upfront license fees						$ 16,730	$ 12,500
Accrued license fees						249,807		$ 233,076
Development and product approval milestones			$ 13,500,000			0
Milestone payments obligation						0
ASO Patent Rights license agreement
Research and development arrangements
Non-refundable license payment	25,000
Non-refundable license payment period (in days)	5 days
Development and product approval milestones			$ 6,750,000
Number of license agreements | item			2
Decoy Patent Rights license agreement
Research and development arrangements
Development and product approval milestones			$ 6,750,000
City of Hope | City of Hope License Agreement
Research and development arrangements
Upfront license fees						7,500	7,500
Additional costs to the company				$ 0
Milestone payments obligation								$ 0
Term of contract					2 years
Common stock issued for R&D milestone						0	62,500
Research and development expense relating to the phase 1 clinical trail						44,000	43,433
City of Hope | City of Hope License Agreement | Kortylewski SRA
Research and development arrangements
Research and development expense relating to the phase 1 clinical trail						$ 50,722	$ 0

Stockholders' Equity - Preferre

Stockholders' Equity - Preferred and Common Stock (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) Vote $ / shares shares	Dec. 31, 2022 $ / shares shares
Stockholders' Equity
Preferred stock, shares authorized (in shares) | shares	20,000,000	20,000,000
Preferred stock, par value per share (in dollars per share) | $ / shares	$ 0.001	$ 0.001
Common stock, shares authorized (in shares) | shares	50,000,000	50,000,000
Common Stock, par value per share (in dollars per share) | $ / shares	$ 0.001	$ 0.001
Common stock, number of votes per share | Vote	1
Proceeds from Scopus Private Placement | $	$ 924,500
Subscriptions receivable | $	$ 25,000
Number of shares issued (in shares) | shares	18,490,000
Common stock issued, value per share | $ / shares	$ 0.05

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants (Details) - USD ($)		1 Months Ended	3 Months Ended
	Feb. 04, 2020	Oct. 31, 2022	Mar. 31, 2023
Stockholders' Equity
Number of shares/units called by each warrant (in shares)			1
Number of warrants outstanding			1,414,539
Share of common stock each			1
Number of warrants exercisable			250,000
Weighted-average exercise price of warrants exercisable			$ 1.50
Scopus warrants outstanding			1,414,539
Exchange agreement
Stockholders' Equity
Number of warrants outstanding		10,439,670
Number of shares issued in recapitalization		20,879,340
Scopus warrants outstanding		10,439,670
Series B Unit | Common Stock
Stockholders' Equity
Number of shares in each unit (in shares)	1
Duet
Stockholders' Equity
Deficit in noncontrolling interest		$ 379,522
Duet
Stockholders' Equity
Percentage of financial interest held		90%	98%
Series W Warrants
Stockholders' Equity
Number of warrants outstanding			1,164,539
Number of warrants exercisable			1,414,539
Weighted-average exercise price of warrants exercisable			$ 3.56
Remaining weighted average contractual term of warrants			3 years 3 months 18 days
Scopus warrants outstanding			1,164,539
Series W Warrants | Series A Units
Stockholders' Equity
Weighted-average exercise price of warrants outstanding	$ 4
Series W Warrants | Series B Unit
Stockholders' Equity
Number of shares/units called by each warrant (in shares)	1
Share of common stock each	1
Series W Warrants | Class B Common Stock | Exchange agreement
Stockholders' Equity
Number of shares/units called by each warrant (in shares)		1,043,989
Share of common stock each		1,043,989
Series W Warrants | Duet | Class B Common Stock | Exchange agreement
Stockholders' Equity
Number of shares/units called by each warrant (in shares)		0.1
Share of common stock each		0.1
Series Z Warrant | Series B Unit
Stockholders' Equity
Number of shares in each unit (in shares)	1
Number of warrants in each unit (in shares)	1
Weighted-average exercise price of warrants outstanding	$ 5

Stockholders' Equity - AIOs (De

Stockholders' Equity - AIOs (Details) - $ / shares		3 Months Ended
	Jan. 18, 2022	Mar. 31, 2023
Stockholders' Equity
Scopus warrants outstanding		1,414,539
Purchase price		$ 0.05
Placement Agent
Stockholders' Equity
Class of warrant or rights year from which warrants or rights exercisable	5 years
Exercise price	$ 4.0625
Number of AIO's to purchase common stock		225,000
Series A Additional Investment Options
Stockholders' Equity
Class of warrant or rights year from which warrants or rights exercisable	5 years
Exercise price	$ 3.125
Series B Additional Investment Options
Stockholders' Equity
Class of warrant or rights year from which warrants or rights exercisable	5 years
Exercise price	$ 3.125
Number of AIO's to purchase common stock		1,500,000
Purchase price		$ 3.25
Additional Investment Options (AIOs)
Stockholders' Equity
Scopus warrants outstanding		3,225,000
Weighted-average exercise price of warrants outstanding		$ 3.19
Remaining contractual term of warrants		3 years 7 months 6 days
Number of AIO's to purchase common stock		1,500,000

Stockholders' Equity - Continge

Stockholders' Equity - Contingent Common Stock (Details) shares in Millions	3 Months Ended
	Mar. 31, 2023 shares
Stockholders' Equity
Number of contingent shares to be receivable by shareholders	1.3

Stockholders' Equity - Noncontr

Stockholders' Equity - Noncontrolling Interest (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) Vote shares	Dec. 31, 2022 USD ($) $ / shares	Oct. 31, 2022
Stockholders' Equity
Proceeds from issuance of warrants and shares	$ 899,500
Subscriptions receivable	25,000
Duet Private Placement
Stockholders' Equity
Proceeds from issuance of warrants and shares	1,365,668	$ 276,065
Additional proceeds from issuance of warrants and shares	1,089,603
Issuance costs	84,072
Stock subscription receivable	3,578	$ 33,950
Offering price (per share) | $ / shares		$ 2.50
Duet
Stockholders' Equity
Proceeds from issuance of warrants and shares	$ 276,065
Percentage of financial interest held	98%		90%
Duet | Exchange agreement
Stockholders' Equity
Number of additional shares of capital stock authorized | shares	50,000,000
Duet | Exchange agreement | Class B Common Stock
Stockholders' Equity
Number of votes per share | Vote	1
Number of shares issued per unit / share | shares	1
Duet | Exchange agreement | Class A Common Stock
Stockholders' Equity
Number of votes per share | Vote	10
Number of shares issued per unit / share | shares	1
Duet
Stockholders' Equity
Increase to the deficit of non-controlling interest from issuance of equity	$ 35,228

Stock Options - Stock option ac

Stock Options - Stock option activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Options
Outstanding at beginning balance	772,500
Outstanding at ending balance	772,500	772,500
Vested and exercisable at March 31, 2023	701,801
Unvested at March 31, 2023	70,699
Weighted-average Exercise Price
Outstanding beginning balance	$ 5.15
Outstanding at ending balance	5.15	$ 5.15
Vested and exercisable at March 31, 2023	5.11
Unvested at March 31, 2023	$ 5.50
Weighted-average Remaining Contractual Life
Options, weighted-average remaining contractual life	3 years 11 months 12 days	4 years 2 months 12 days
Vested and exercisable at March 31, 2023	4 years 25 days
Unvested at March 31, 2023	2 years 8 months 15 days

Stock Options - Additional Info

Stock Options - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Sep. 24, 2018
Stock Options
Option issued to underwriters	772,500		772,500
Stock-based compensation associated with vesting options	$ 78,108	$ 95,028
Total unrecognized stock-based compensation expense	$ 220,887
Remaining weighted-average contractual vesting term	8 months 12 days
Over-allotment option
Stock Options
Option issued to underwriters	172,500
2018 Equity Incentive Plan
Stock Options
Shares reserved for future issuance	1,800,000			1,000,000
Increase in shares reserved for future issuance				2,400,000
Vesting period (in years)	3 years

Related Party Transactions - Po

Related Party Transactions - Portfolio Services (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Indemnification Agreement
Related Party Transactions
Legal and other related professional fees	$ 0	$ 16,585
Portfolio Services
Related Party Transactions
Monthly management services fee	50,000
Monthly facilities fee	3,000
Expense from related party transaction	159,000	159,000
Amounts payable	75,000		$ 50,706
Clil Medical Ltd
Related Party Transactions
Expense from related party transaction	0	$ 0
Due to related parties	$ 198,530		$ 198,530

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	May 08, 2023	Apr. 30, 2023	Mar. 31, 2023
Subsequent Events
Common stock issued, value per share			$ 0.05
Subsequent Events
Subsequent Events
Aggregate purchase price	$ 2.3
Common stock issued, value per share	$ 0.05
Warrants purchased		3,000,000